[1]杨义明,张水兰,宋华勇,等.TP方案治疗难治性晚期食管鳞癌的临床观察[J].南方医科大学学报,2004,(09):1042-1044.
 YANG Yi-ming,ZHANG Shui-lan,SONG Hua-yong,et al.Clinical observation of TP regiment for treating refractory and terminal squamous cancer of the esophagus[J].Journal of Southern Medical University,2004,(09):1042-1044.
点击复制

TP方案治疗难治性晚期食管鳞癌的临床观察()
分享到:

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2004年09期
页码:
1042-1044
栏目:
出版日期:
2004-09-01

文章信息/Info

Title:
Clinical observation of TP regiment for treating refractory and terminal squamous cancer of the esophagus
作者:
杨义明 张水兰 宋华勇 李旭
河南大学第一附属医院肿瘤科, 河南, 开封, 475001
Author(s):
YANG Yi-ming ZHANG Shui-lan SONG Hua-yong LI Xu
Department of Oncology, First Affiliated Hospital of Henan University, Kaifeng 475001, China
关键词:
紫杉醇顺铂联合化疗晚期食管鳞癌难治性
Keywords:
taxolcisplatincombined chemotherapyrefractory terminalesophagus carcinoma squamous
分类号:
R735.1
摘要:
目的 观察国产紫杉醇(TAX)联合顺铂(PDD)组成的TP方案治疗难治性晚期食管癌的疗效及其不良反应。方法 64例经PF方案化疗2周期后无效的难治性Ⅳ期食管鳞癌患者,应用TP方案化疗,即紫杉醇175 mg/m2,静脉恒速滴注3 h,d1;顺铂30 mg/d,静脉滴注,避光,d2~6;28 d为1个周期,连用3个周期后评价近期疗效及不良反应。结果 全组64例患者共完成TP方案化疗192周期,均可评价疗效,共获得CR 9例、PR 29例、SD 12例、PD 14例,客观有效率为59.4%,中位缓解期为4.8个月,中位TTP为4.4个月,中位生存期为9.8个月(4~28个月)。主要不良反应为骨髓抑制。结论 TP方案治疗难治性晚期食管鳞癌近期疗效肯定,不良反应可以耐受,值得临床进一步研究。
Abstract:
Objective To evaluate the therapeutic efficacy and adverse effects of TP regimen consisting of taxol (TAX) and cisplatin (DDP) for treating refractory and terminal squamous cancer of the esophagus. Methods Totally 64 patients with stage IV squamous cancer of the esophagus, who failed to respond to a tow-course regiment, were treated with TP regimen with intravenous infusion of TAX 175 mg/m2 on day 1 and DDP 30 mg/d on days 2-6. After 3 consecutive treatment course, each for 28 days, evaluation of the short-term efficacy and adverse effects was carried out. Results All the 64 patients completed altogether 192 treatment courses of TP regiment, resulting in a total response rate of 59.4% including 9 patients with complete remission (CR) and 29 with partial remission (PR). Stabilization (SD) was achieved in 12 patients while 14 failed to respond favorably and had further progression (PD) of the disease. The median remission duration was 4.8 months, median TTP 4.4 months and median survival of 9.8 months (4-28 months). The main adverse effect of the regimen was bone marrow depression. Conclusion TP regimen for treating refractory and terminal squamous cancer of the esophagus is clinically effective and well tolerated.

参考文献/References:

[1] 中国肿瘤防治研究办公室卫生部统计信息中心.中国试点市、县恶性肿瘤的发病与死亡[M].北京:中国医药科技出版社,2002.28-34.
[2] 宋维舒.放疗后化疗治疗食管癌96例疗效分析[J].第一军医大学学报(J FirstMilMedUniv/DiYi JunYiDaXueXuegao),2001,21(9):703-4.
[3] 徐绮腻,江艺,邱希辉,等.大剂量醛氢叶酸加5-氟尿嘧啶持续48小时滴注联合顺铂治疗晚期食管与贲门癌初步观察[J].临床肿瘤学杂志(Chin Clin Oncol),2003,8(1):23-5.
[4] 李醒亚,申淑景,王瑞林,等.紫杉醇治疗食管癌疗效分析[J].癌症(Cancer),1999,18(3):327-9.
[5] 王留兴,李醒亚,王瑞林,等.顺铂加5-氟尿嘧啶联合治疗晚期食管癌156例[J].中华肿瘤杂志(Chin JOnco1),1999,12(6):389-91.
[6] 张阳,王瑞林,樊青霞,等.食管癌增效化疗的基础与疗效[J].河南肿瘤学杂志(Henan J Onco1),2003,16(1):74-8.
[7] Klauber N, Parangi S, Flynn E, et al. Inhibition ofangiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol[J]. Cancer Res, 1997, 57(1): 81-6.
[8] 梅静峰,秦叔逵,钱军,等.紫杉醇联合顺铂治疗复治性中晚期食管癌贲门癌的临床研究[J].临床肿瘤学杂志(ChinClinOnco1),2003,(4):272-5.

相似文献/References:

[1]余乐,陈明辉,古春萍,等.顺铂下调铜离子转运蛋白1诱导人食管鳞癌细胞EC109耐药[J].南方医科大学学报,2011,(05):801.
[2]林晓丹,石兴源,周同冲,等.调强或三维适形放疗联合TP 方案化疗治疗局部中晚期食管癌的临床研究[J].南方医科大学学报,2011,(07):1264.
[3]陈斯泽,陈雪梅,丁颖,等.Combined chemotherapy with cisplatin, docetaxel and capecitabine for metastatic nasopharyngeal carcinoma:a retrospective analysis[J].南方医科大学学报,2011,(07):1114.
[4]彭萍,吴璇,关婷,等.1-磷酸-神经鞘氨醇干预化疗对荷瘤小鼠卵巢功能和抑瘤效果的影响[J].南方医科大学学报,2012,(03):383.
[5]崔斐,罗荣城,陈锦章,等.紫杉醇联合Herceptin或表阿霉素治疗Her-2/neu阳性乳腺癌患者的临床疗效[J].南方医科大学学报,2005,(12):1533.
 CUI Fei,LUO Rong-cheng,CHEN Jin-zhang,et al.Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu[J].Journal of Southern Medical University,2005,(09):1533.
[6]万海燕,朱国英,王人彭,等.紫杉醇洗脱支架治疗冠状动脉硬化性心脏病近期效果[J].南方医科大学学报,2005,(10):1299.
 WAN Hai-yan,ZHU Guo-ying,WANG Ren-peng,et al.Short-term effect of paclitaxel-eluting stent in the treatment of coronary heart disease due to coronary arteriosclerosis[J].Journal of Southern Medical University,2005,(09):1299.
[7]孙明,杨宇如,李虹,等.紫杉醇和吉西他滨对激素非依赖性前列腺癌的作用[J].南方医科大学学报,2004,(09):1009.
 SUN Ming,YANG Yu-ru,LI Hong,et al.Synergistic effects of paclitaxel and gemcitabine on androgen-independent prostate cancer[J].Journal of Southern Medical University,2004,(09):1009.
[8]冯正富,潘辉林,宋慧胜,等.同期放化疗治疗中晚期鼻咽癌临床研究[J].南方医科大学学报,2004,(06):694.
 FENG Zheng-fu,PAN Hui-lin,SONG Hui-sheng,et al.Radiotherapy with concurrent chemotherapy for treatment of advanced nasopharyngeal carcinoma[J].Journal of Southern Medical University,2004,(09):694.
[9]余元龙,季明芳,何洁冰,等.紫杉醇、5-氟脲嘧啶抑制肝癌细胞BEL-7402生长和诱导凋亡的比较[J].南方医科大学学报,2005,(07):864.
 YU Yuan-long,JI Ming-fang,HE Jie-bing,et al.Effects of paclitaxel and 5-fluorouracil on growth inhibition and apoptosis of hepatoma cells:a comparative study[J].Journal of Southern Medical University,2005,(09):864.
[10]曹漫明,张积仁,汪森明,等.卵巢癌顺铂耐药细胞中DNA转录与修复相关基因的表达[J].南方医科大学学报,2005,(12):1478.
 CAO Man-ming,ZHANG Ji-ren,WANG Sen-ming,et al.Expression of DNA transcription-and repair-related genes in cisplatin-resistant human ovarian carcinoma cell line COC1/DDP[J].Journal of Southern Medical University,2005,(09):1478.

备注/Memo

备注/Memo:
收稿日期:2004-6-3。
作者简介:杨义明(1966-),男,1986年毕业于河南医科大学,本科,副主任医师,电话:0378-5661692,E-mail:yangymch@sina.com
更新日期/Last Update: 1900-01-01